key: cord-0846821-3vhg3i31
authors: Kula, B.; Clancy, C. J.; Nguyen, M. H.; Schwartz, I. S.
title: Invasive Mould Disease in Fatal COVID-1 19: A Systematic Review of Autopsies
date: 2021-01-20
journal: nan
DOI: 10.1101/2021.01.13.21249761
sha: 11c0189818eb6ea71dbe3a108a48450df3d6a1c0
doc_id: 846821
cord_uid: 3vhg3i31

Background Invasive mould disease (IMD) - most commonly pulmonary aspergillosis - is reported to affect up to a third of critically ill COVID-19 patients. Most reported cases are diagnosed with probable/putative COVID-19 associated pulmonary aspergillosis (CAPA) based on a combination of non-specific clinical, radiographic, and mycological findings, but the clinical significance - and whether these cases represent true invasive disease - is unresolved. Methods We performed a systematic review of autopsy series of decedents with COVID-19 for evidence of IMD. We searched PubMed, Web of Science, OVID (Embase) and MedRxiv for English- or French-language case series published between January 1, 2019 to September 26, 2020. We included series describing lung histology of [≥]3 decedents, and authors were contacted for missing information as necessary. Results We identified 51 case series describing autopsies of 702 decedents. Individual-level data was available for 430 decedents. The median age was 72 (IQR 61 to 80) years. Diabetes mellitus, pre-existing lung disease, and immunocompromising conditions were reported for 129 (32%), 95 (22%), and 25 (6%) decedents, respectively. The median hospitalization length was 10 (IQR 5-22) days. 51.6% of decedents had received mechanical ventilation for a median of nine (IQR 5-20) days. Treatment included immunomodulation in 60 (most often steroids or tocilizumab) and antifungals in 41 decedents. Eleven decedents (1.6%) had autopsy-confirmed IMD (6 with CAPA, 4 with invasive pulmonary mycosis not specified and 1 with disseminated mucormycosis). Among 173 decedents who received mechanical ventilation, 5 had IMD (2.9%). Conclusions Autopsy-proven IMD, including CAPA, is uncommon in fatal COVID-19.

cases represent true tissue-invasive disease. If they do, then IMD would be expected to be a common 82 finding in post-mortem examinations of decedents with fatal COVID- 19 . 83

Here we present a systematic review of autopsy studies performed in persons with fatal COVID-19 to 84 determine the prevalence of autopsy-proven tissue-invasive IMD and analyze patient-level data to assess 85 potential risk factors. 86

This systematic review follows PRISMA reporting guidelines 19 and the protocol was published as part of 89 a two-study review on PROSPERO (CRD42020204123). We identified possible studies by searching 90

PubMed, Web of Science, OVID (Embase) and MedRxiv for articles published from January 1, 2019 to 91

September 26, 2020. We used the terms "sars cov2" OR "covid" OR "2019 ncov" OR "novel 92 coronavirus" AND "autopsy" OR "post-mortem". We also reviewed reference lists of eligible 93 publications for additional articles of interest as well as personal databases maintained by the authors. We 94 contacted authors of reports to obtain missing details when required or if the outcome of interest (fungal 95 infections) was not described. We only included articles written in English or French. 96

Studies met inclusion criteria if they were retrospective or prospective case series of autopsy or post-97 mortem reports of decedents with confirmed SARS-CoV-2 infection. In order to minimize reporting bias 98 from case reports (either of IMD or competing diagnoses), we only included series with at least three 99 decedents. At minimum, the examination must have included histopathologic investigation of the lungs 100 either through standard or minimally invasive sampling. Studies were excluded if decedents were 101 included or excluded based on diagnoses other than COVID-19, or the presence or absence of 102 review was then performed independently by the same two authors (BEK, ISS) for final inclusion. A 106 consensus was reached for all disputes. COVIDENCE was used for abstract management (Veritas Health 107

Innovation, Melbourne, Australia available at www.covidence.org). 108

In the instance of decedents being included in more than one report, we included the study with the most 109 patient-related variables unless that which contained less individual data had a case of CAPA. If there 110 were more decedents included in the less detailed study, we still extracted data for these remaining 111 patients to add to the total cohort but did not extract any additional patient-level details. When a pre-print 112 went on to be published, we preferentially included publications and excluded the pre-prints as these were 113 not picked up as duplicate studies by our abstract manager. 114

Outcomes 115

The main outcome of interest was the number of decedents with autopsy-proven invasive mould disease 116 (IMD) determined by histopathology showing hyphae invading tissue. When available, we recorded the 117 type of mould as identified in the reports. We recorded the types of autopsies performed as either standard 118 or minimally invasive. Minimally invasive included any autopsy in which multiple lung tissue samples 119 from each lobe were obtained either blindly or through ultrasound guidance; this practice has been 120 applied frequently in COVID-19 to limit occupational exposures at the time of autopsy. We also recorded 121 study country of origin and place of death (hospitalization or community). When possible, individual 122 patient data were also extracted. We collected patient age, comorbidities, length of hospital stay, duration 123 of symptoms, days of mechanical ventilation, and immunomodulatory COVID-19-specific treatment 124 prescribed (i.e. cytokine inhibitors or steroids). We used EORTC/MSGERC definitions of host factors to 125 classify whether decedents were immunocompromised. 17 126

We did not judge the study quality given these are small case series without a target intervention. We 128 attempted to guard against selective reporting by contacting corresponding authors for any manuscript in 129 which the outcome of interest (fungal infection) was not described. We also attempted to mitigate small-130 study effect by including only those series with three or more cases described. 131

There was no funding source for this study. 133

We identified 1,070 references from the database searches and 4 from alternative sources; 454 were 135 duplicates, 526 were excluded from title and abstract review and an additional 39 from full text review 136 leaving 51 studies meeting criteria for data extraction (Figure 1 ). Of these, six were pre-prints and the 137 remainder were published in peer-reviewed journals. All studies were published in 2020. 138

A total of 702 decedents were described across the 51 studies (Table 1) . 139

Studies were included from 15 countries, most commonly from the USA (including 224 decedents), Italy 140 (146) and Germany (84) (Figure 2 both of these drug classes; 48 received steroids; and details of immunomodulatory therapy missing for 157 one). Forty-one decedents (9·5%) were recorded to have received antifungals. 158

Among the total cohort of 702 decedents, 11 (1·6%) had autopsy evidence of IMD, including six (0·9%) 159 described as pulmonary aspergillosis, four (0·6%) with invasive mycoses not specified, and one (0·1%) 160 with mucormycosis (Table 2) . Among decedents with CAPA, disease was limited to the airways in one, 161

involved only the lungs in four, and both airways and lung in one case. Of the decedents with unidentified 162 IMD, disease was confined to the airways in one, and was found in the lungs in three. In the patient with 163 mucormycosis, fungal invasion was demonstrated in lungs, hilar lymph nodes, brain, and kidney. Of 430 164 decedents with individual-level data, nine (2·1%) had autopsy-proven IMD including five (1·2%) with 165 CAPA, three with unidentified invasive moulds (0·7%) and one with mucormycosis. Decedents with and 166 without IMD that had patient-level data available are compared in Table 3 . 167

Two decedents with IMD (22·2%) had pre-existing immunocompromising conditions vs 23 (5·3%) 168 without CAPA. In one immunocompromised decedent in the IMD group, the diagnosis of aspergillosis 169 pre-dated COVID-19 62 (Sanjat Kanjilal Brigham and Women's Hospital, personal communication). Only 170 one decedent (11·1%) with IMD received immunomodulatory therapy for COVID-19 compared to 59 171 (13·7%) without IMD. One decedent with IMD (11·1%) was recorded to have received antifungals. 172

In this systematic review of autopsy studies, we describe the prevalence of autopsy-proven IMD including 174 CAPA among persons with fatal COVID-19 infections. IMD was autopsy-proven in just 1·6% of all 175 decedents with COVID-19 and 2·9% among those reported to have received mechanical ventilation. 176 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.13.21249761 doi: medRxiv preprint

The rates of autopsy-proven IMD are considerably lower than rates of CAPA reported from ICU cohort 180 studies. In a systematic review of ICU cohort studies, the median prevalence of CAPA was 21.1% (IQR 181 15.2-27.5%) (unpublished data). Given that post-mortem examinations are the most reliable way to 182 confirm IMD, this review provides a more robust appraisal of the true prevalence of IMD complicating 183 critical COVID-19 and suggests that the high CAPA rates published from cohort studies may be due to 184 over-diagnosis. Indeed, previous autopsy studies have shown that pneumonias, in general, were over-185 called antemortem, and that discrepancy rates between clinical and necropsy findings were higher for 186 respiratory tract infections than for other types of infection. 71 

CAPA may be over-diagnosed in ICU studies because of a lack of specificity in the classification of 188 probable/putative and possible CAPA (which characterize the vast majority of cases reported to date). 189

Indeed, there are several challenges that ICU studies face in determining the true prevalence of CAPA. were severe by definition, given that they resulted in death. However, only 45% of decedents had 221 received mechanical ventilation. Five of eight decedents with autopsy-proven IMD (62·5%) for whom 222 this data was available had received mechanical ventilation (compared to 168/327 without IMD [39·9%]). 223

These data suggest that IMD (including CAPA) is not confined to mechanically ventilated patients and 224 that higher rates in these patients may reflect a combination of disease severity and convenience of 225 testing. 226 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.13.21249761 doi: medRxiv preprint Immune dysregulation is implicated in the pathogenesis of severe COVID-19, and immunomodulatory 227 therapies like corticosteroids and cytokine inhibitors (IL-1 and IL-6 inhibitors) have been widely used. 228

Corticosteroid therapy is a known risk factor for IPA 17 and IL-6 inhibitors could plausibly provoke IMD 229

given impaired immune response to other pathogens. 73 Only one (11·1%) of the nine decedents with IMD 230 for whom treatment data was available had received these drugs, comparable to 14% in the non-IMD 231 group. Importantly, most autopsies were conducted prior to the publication of the RECOVERY trial 232 which showed dexamethasone improved mortality in patients with severe and critical COVID-19, 74 and so 233 corticosteroid prescribing may have increased since then. Further study will be needed to determine 234 whether use of immunomodulatory therapy will be associated with tissue-proven IMD. 235

Post-mortem examination is the most definitive means available to detect IMD and is a particular strength 236 of this study. The presence of hyphae on histopathologic investigation is simple to detect and it is 237 therefore highly likely that the majority of these cases would have been identified. We also made every 238 effort to contact authors when histopathologic findings were not specifically described to confirm that 239 IMD had not been encountered in each case. Another strength is the inclusive nature of our review, which 240 included pre-prints, given the rapidly expanding literature in Despite these strengths, there are several limitations of this study that should be considered. First, we only 242 included studies published in English or French, and it is possible that excluded studies could have 243 contributed further data. Second, we were confronted with limited patient information from most reports. 244

Use of antifungals was not commonly reported, and we cannot be sure whether this reflects incomplete 245 data or low rates of prescribing. Antifungal use could have reduced the sensitivity of IMD detection on 246 autopsy. The use of immunomodulators was also incompletely reported. While this would be unlikely to 247 affect the main findings, this data could be helpful in the understanding of risk of tissue-proven IMD 248 associated with these therapies. Third, although our review was exhaustive, the sample size is very small 249 compared the total number of COVID-19 deaths internationally; most decedents were included from just 250 three countries (US, Germany, Italy) and geographic variation in incidence of IMD following COVID-19 251 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.13.21249761 doi: medRxiv preprint may occur (as it does following influenza). 75 Fourth, while the use of minimally invasive autopsy 252 strategies for COVID-19 have been validated, 25,33,76 random sampling rather than whole lung examination 253 may have led to under-diagnosis of IMD; it is re-assuring, however, that the majority of our included 254 cases were performed with standard technique. 255

In conclusion, autopsy-proven IMD is uncommonly reported among decedents with COVID-19. In order 256 to further our understanding of the prevalence of IMD, future autopsy studies should include patients with 257

ante-mortem diagnoses of CAPA to validate clinical definitions for this disease. Future autopsy studies 258 should specifically consider co-infections and make note of clinical diagnoses and antemortem use of 259 antimicrobials, including antifungals, and of immunomodulatory treatments. 260

Evidence before this study 262

We searched 4 databases dated from January 1, 2019 to September 26, 2020 for studies written in English 263 or French describing lung histopathology in autopsy specimens from decedents with COVID-19, with the 264 view of outlining the prevalence of tissue-invasive mould infection. Estimating the prevalence of CAPA 265

in clinical studies has been limited by scarcity of biopsies in critically ill patients, and reliance on various 266

proposed definitions that combine non-specific clinical, radiographic, and microbiological findings to 267 make diagnoses of probable (putative) or possible CAPA. There are currently no published systematic 268 reviews focusing on COVID-19 autopsy cases for secondary IMD, including CAPA, which would be 269 needed to meet definitive criteria. 270

We did a systematic review of autopsy series including ≥3 decedents diagnosed preor post-mortem with 272 COVID-19 and identified 51 studies that met inclusion criteria. Data was from 16 countries and identified 273 702 decedents. Given that tissue sampling is the gold standard for diagnosis of IMD, this is the best 274 available evidence to support that IMD including CAPA is rare in COVID-19 patients. This was far less 275 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.13.21249761 doi: medRxiv preprint common (1·7%) than that reported in clinical case series. There was inconsistent reporting to review 276 potential risk factors including immunocompromised status, invasive mechanical ventilation, and 277 exposure to immunomodulatory therapy. 278

Our findings suggest that tissue-invasive IMD including CAPA and complicating COVID-19 is rare. The 280 presence of aspergillosis on culture is not diagnostic of clinical infection and may represent colonization. 281

Further autopsy studies specifically directed at fungal super-infections would be optimal to further 282 delineate the true frequency of infection. 283

BEK conducted the literature search and wrote the first draft of the manuscript. BEK and ISS did the 285 review, data extraction and analysis, and created the figures. ISS was responsible for study design and 286 overall supervision. All authors contributed to the data interpretation, and to critical revision of the 287 manuscript. 288

We declare no competing interests. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 393 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. Legend: * author contacted, † sufficient information for patient-level data extraction, ‡ some decedents included in other cohort therefore patient number reduced, ND not documented Table 1 : Summary of studies meeting criteria for data extraction All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.13.21249761 doi: medRxiv preprint Legend: *pre-existing diagnosis, allo-HSCT allogeneic stem cell transplant, B-ALL b-cell acute lymphoblastic leukemia, GVHD graft versus host disease, IMV invasive mechanical ventilation, NA not applicable (not individual patient data in study), ND not documented Legend: Data presented as n (%) unless otherwise specified. *data missing for 60, † data missing for 29, ‡ data missing for 3, § data missing for 167, ¶ data missing for 5, || data missing for 112, **data missing for 1, † † data missing for 94, ‡ ‡ data missing for 5, § § data missing for 33 Table 3 : Patient-level data for decedents with and without autopsy-proven invasive mould disease Table 3 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.13.21249761 doi: medRxiv preprint

Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with 417 immunohistochemical and viral RNA studies

situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19

Postmortem examination of patients with COVID-19

Viral presence and immunopathology in patients with lethal COVID-19: A prospective 423 autopsy cohort study

Post-mortem viral dynamics and tropism in COVID-19 patients in 425 correlation with organ damage

Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem 427 core biopsies

Increased number of pulmonary megakaryocytes in COVID-19 patients 429 with diffuse alveolar damage: An autopsy study with clinical correlation and review of the literature

Autopsy findings and venous thromboembolism in patients with

COVID-19: The key role of pulmonary capillary leakage. an observational cohort study

COVID-19 autopsy in people who died in community settings: The first series

Discrepancies between clinical and postmortem diagnoses in Jamaica: A 438 study from the university hospital of the West Indies

Decedents Included